#Oligonucleotide Synthesis Market size

[industrynewsupdates]

Oligonucleotide Synthesis Market Analysis And Segment Forecast 2024-2030

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Oligonucleotide Synthesis Market Segmentation

Grand View Research has segmented the global oligonucleotide synthesis market report based on product & service, application, and region:

Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• Oligonucleotides

o DNA

o Column-based

o Array-based

o RNA

o By Technology

o Column-based

o Array-based

o By Type

o Short RNA Oligos (<65 nt)

o Long RNA Oligos (>65 nt)

o CRISPR (sgRNA)

• Equipment/Synthesizer

• Reagents

• Services

o DNA

o Custom Oligo Synthesis Services

o 25 nmol

o 50 nmol

o 200 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

o RNA

o Custom Oligo Synthesis Services

o 25 nmol

o 100 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

Application Outlook (Revenue, USD Million, 2018 - 2030)

• PCR Primers

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• PCR Assays & Panels

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Sequencing

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• DNA Microarrays

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Fluorescence In Situ Hybridization (FISH)

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Antisense Oligonucleotides

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Other Applications

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Spain

o Italy

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

• The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher Corporation

• Dharmacon Inc.

• Agilent Technologies

• Bio-synthesis

• Kaneka Eurogentec S.A

• LGC Biosearch Technologies

• Biolegio

• Twist Bioscience

Recent Developments

• In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

• In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

• In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

• In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

• In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[poonamcmi]

Oligonucleotide Synthesis Market is Expected to Witness High Growth Owing to Rising Biotechnology Research and Development

The oligonucleotide synthesis market involves the production of shorter sequences of nucleic acids known as oligonucleotides that are widely used in research, diagnostics and therapeutics applications. Oligonucleotides play a vital role in gene expression studies, next-generation sequencing, DNA & RNA analysis, qPCR and molecular diagnostics. The increasing focus on biotechnology research especially in life sciences and genomics has boosted the demand for specialized oligonucleotides.

The Global oligonucleotide synthesis market is estimated to be valued at US$ 4565 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period of 2024 to 2031.

Key Takeaways Key players operating in the oligonucleotide synthesis are Forte Research Systems (India), ICON plc (Ireland), Merge healthcare incorporated (U.S.), Bio-Optronics (U.S.), DSG INC (U.S.), ArisGlobal (India), ERT Clinical Bioclinica (U.S.), Oracle Corporation (U.S.), Medidata Solutions (U.S.), DATATRAK International, Inc. (U.S.), and MedNet Solutions, Inc., (U.S.) among others. These key players are focusing on partnerships and new technology development to expand their oligonucleotide synthesis capabilities.

Key Oligonucleotide Synthesis Market Demand include increasing research in personalized medicine and precision genomics. Additionally, the growing pipeline of oligo-based drugs and clinical trials for rare diseases will provide momentum.

With regards to geographical expansion, North America dominates the global oligonucleotide synthesis market followed by Europe. However, Asia Pacific is expected to witness highest growth rate owing to increasing government support for biotech sector and growing industry investments in China and India.

Market Drivers Increasing R&D expenditure for biotechnology research especially in life sciences and biopharmaceutical industry is a key factor contributing to the Oligonucleotide Synthesis Market Size And Trends Oligonucleotides play a vital role in new drug discovery and development which is propelling many biotech companies to adopt oligo synthesis. Rising applications of oligos in development of advanced therapeutics like antisense oligonucleotides and siRNA is expected to drive the market during the forecast period.

PEST Analysis Political: Government regulations around drug research and development have an impact. Changes in healthcare policies and funding also affect the market. Economic: The state of the economy influences research spending by pharmaceutical companies and academic institutions, affecting demand. Rising healthcare costs drive need for new drug therapies. Social: An aging global population with increased prevalence of diseases like cancer is leading to higher demand for advanced drug development and diagnostic tools. Social attitudes around health and biotech also evolve over time.

Technological: Advancements in DNA sequencing, synthesis and analysis technologies enable new applications and drive down costs, expanding the potential market. Automation and artificial intelligence are enhancing R&D productivity.

North America holds the largest share in terms of value currently due to heavy spending on drug R&D by major players in the US and Canada. However, Asia Pacific is expected to grow at the fastest rate during the forecast period as the pharmaceutical industry expands rapidly in major emerging economies like China and India. These countries are making large investments in research and increasing regulatory approvals are also supporting market growth.

Europe accounts for a sizable share as well owing to extensive government funding for research programs. However, the high costs of oligonucleotide therapies has limited their use thus far. If pricing and reimbursement improve in the future, the European market could witness stronger growth. On the other hand, the Middle East and Africa region is relatively nascent but demand may rise over time with economic development across various nations. Get More Insights On, Oligonucleotide Synthesis Market About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, c

[soumyafwr]

Oligonucleotide Synthesis Market Size, Analysis and Forecast 2031

[researchreport11]

https://www.maximizemarketresearch.com/market-report/global-oligonucleotide-synthesis-market/31248/

Oligonucleotide Synthesis Market- Global Industry Analysis and Forecast (2023-2029)

Oligonucleotide Synthesis Market was valued at US$ 5.75 Bn in 2022 and is expected to reach 15.20Bn by 2029, at a CAGR of 14.87% during the forecast period.

[insightslicelive]

Oligonucleotide Synthesis Market 2022 Players Targeting Application to Boost Growth by 2032 | Biosearch Technologies, Bioneer Corp, Kaneka Corp

Oligonucleotide Synthesis Market 2022 Players Targeting Application to Boost Growth by 2032 | Biosearch Technologies, Bioneer Corp, Kaneka Corp

“ The Oligonucleotide Synthesis Market research report provides detailed observation of several aspects, including the shift in rate of growth, regional scope and recent developments by the primary market players. The report offers Porter’s Five Forces, PESTLE analysis to provide a complete research study on the global Oligonucleotide Synthesis market. The research study discusses about…

[domberaj38]

According to Nova one advisor, the global Oligonucleotide Synthesis market gathered revenue around USD 4.9 Billion in 2020 and market is set to grow USD 16.9 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 18.9% during the prediction period 2021 to 2027.

[luckydige45]

According to Nova One Advisor, the U.S. oligonucleotide synthesis market size was valued at USD 1.55 billion in 2023 and is anticipated to reach around USD 5.22 billion by 2033, growing at a CAGR of 12.90% from 2024 to 2033.

[aarunresearcher]

The increasing prevalence of various chronic diseases in the United States like cancer represents one of the primary factors stimulating the market growth. Oligonucleotides are widely used in the development of advanced diagnostic tools, such as liquid biopsy tests and molecular diagnostics for infectious diseases. Additionally, the growing trend of personalized medicine is catalyzing the demand for oligonucleotides for diagnostics and therapies, propelling the market growth. 

[aimarketresearch]

Global Oligonucleotide Synthesis Market Market Size, Share, Trends, Demand, Growth and Competitive Analysis

Oligonucleotide Synthesis Market research report has been prepared with the systematic gathering and evaluation of market information for  industry which is presented in a form that explains various facts and figures to the business. Report saves valuable time as well as adds credibility to the work that is performed to grow business. This quality report has been planned with full commitment and transparency in research and analysis. With the systematic insights of this report, companies can self-assuredly take decisions about the production and marketing strategies. Oligonucleotide Synthesis Market document provides the same by studying the market and the  industry with respect to numerous aspects.

Oligonucleotide Synthesis Market report gives explanation about the different segments of the market analysis which is demanded by today’s businesses. Key players are taking actions such as developments, product launches, acquisitions, mergers, joint ventures and competitive analysis in the  industry. All the market aspects are estimated and analysed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the report. Global Oligonucleotide Synthesis Market research report, it becomes easy to figure out brand awareness and insight about the brand and product among potential customers.

Oligonucleotide Synthesis Market, By Product (Oligonucleotide, Reagents, and Equipment), Type (Custom Oligos and Predesigned Oligos), Application (Therapeutic Applications, Diagnostics, Research, and Others), End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories and others) - Industry Trends and Forecast to 2030.

Access Full 350 Pages PDF Report @

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Oligonucleotide Synthesis Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Oligonucleotide Synthesis Market.

Global Oligonucleotide Synthesis Market survey report analyses the general market conditions such as product price, profit, capacity, production, supply, demand, and market growth rate which supports businesses on deciding upon several strategies. Furthermore, big sample sizes have been utilized for the data collection in this business report which suits the necessities of small, medium as well as large size of businesses. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies.

The following are the regions covered in this report.

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

The Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

This study answers to the below key questions:

What are the key factors driving the Oligonucleotide Synthesis Market?

What are the challenges to market growth?

Who are the key players in the Oligonucleotide Synthesis Market?

What are the market opportunities and threats faced by the key players?

Some of the major players operating in the global oligonucleotide synthesis market are:   

Agilent Technologies, Inc. (U.S.)

Atdbio Ltd.(U.K.)

LGC Limited (U.K.)

Bio-Synthesis Inc.(U.S.)

Eurofins Genomics (India),

Kaneka Eurogentec S.A.(Belgium)

General Electric (U.S.)

Genscript (U.S.)

AJINOMOTO CO.,INC (Genedesign, Inc.) (Tokyo)

Danaher (U.S.)

Merck Kgaa (Germany)

Browse Trending Reports:

Telehealth Market Size, Share, Trends, Growth Opportunities and Competitive Outlook https://www.databridgemarketresearch.com/reports/global-telehealth-market

Digital Health Technologies Market Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook https://www.databridgemarketresearch.com/reports/global-digital-health-technologies-market

Active Pharmaceutical Ingredient Api Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis https://www.databridgemarketresearch.com/reports/global-active-pharmaceutical-ingredient-api-market

Clinical Oncology Next Generation Sequencing Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis https://www.databridgemarketresearch.com/reports/global-clinical-oncology-next-generation-sequencing-market

Generic Drug Market Size, Share, Trends, Growth Opportunities and Competitive Outlook https://www.databridgemarketresearch.com/reports/global-generic-drug-market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[tamanna31]

New Trends of Oligonucleotide Synthesis Market with Industry Analysis by 2024 – 2030

Oligonucleotide Synthesis Industry Overview

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

·         Thermo Fisher Scientific, Inc.

·         Merck KGaA

·         Danaher Corporation

·         Dharmacon Inc.

·         Agilent Technologies

·         Bio-synthesis

·         Kaneka Eurogentec S.A

·         LGC Biosearch Technologies

·         Biolegio

·         Twist Bioscience

Recent Developments

In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[industrynewsupdates]

Active Pharmaceutical Ingredients Market: Key Companies and Emerging Trends 2024-2030

The global active pharmaceutical ingredients market size was estimated at USD 237.47 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.75% from 2024 to 2030. 

Advancements in Active Pharmaceutical Ingredient (API) manufacturing, growth of the biopharmaceutical sector, and an increase in geriatric population are among the key drivers of API market. An increase in prevalence of chronic diseases, such as cardiovascular diseases and cancer, is anticipated to boost market growth.

Global geriatric population is increasing. According to UN, in 2022, people aged 65 and above accounted for 771 million of the population, and the number is anticipated to reach 994 million by 2030 to 1.6 billion by 2050. The number of elderly people is showing fastest growth in Africa, with a threefold increase estimated in people aged 60 and above, followed by Latin America, reaching 18.8 billion by 2050. Aging is considered the greatest risk factor for development of diseases, including cardiovascular and neurological diseases. Thus, rapidly growing global geriatric population is resulting to be a high-impact-rendering driver for API market.

Gather more insights about the market drivers, restrains and growth of the Active Pharmaceutical Ingredients Market

Increasing prevalence of infectious diseases and hospital-acquired infections is driving market growth. In addition, growing incidence of cardiovascular, genetic, and neurologic disorders is anticipated to act as a high-impact-rendering driver for market growth. Cardiovascular Diseases (CVDs) are the most prevalent causes of death globally. According to WHO, cardiovascular diseases cause death of 17.9 million people per day and are expected to cause approximately 25 million deaths by 2030. Increasing epidemiology of lifestyle, aided with rising number of smokers globally, growing incidence of obesity, and increasing dietary irregularities, are factors likely responsible to propel market growth. A recent report by the United Nations (UN) in May 2023 suggests that there has been a 75% increase in the number of girls and 61% in the number of boys with obesity in Europe.

Outsourcing of APIs has become profitable over in-house production. However, this trend took a different turn during the COVID-19 pandemic. Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer. In addition, risk mitigation is done using dual sourcing to ensure a continuous supply. Hence, key companies aim to capitalize on this ongoing outsourcing trend with new acquisitions. For instance, in August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry. This further demonstrates the company’s plans for vertical integration.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global antipsychotic drugs market size was valued at USD 16.88 billion in 2023 and is projected to grow at a CAGR of 6.1% from 2024 to 2030. 

• The global drug and gene delivery devices market size was valued at USD 670.0 million in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030.

Active Pharmaceutical Ingredients Market Report Segmentation

Grand View Research has segmented the global active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, application, type of drug, and region:

Type of Synthesis Outlook (Revenue, USD Billion, 2018 - 2030)

• Biotech

o Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)

o Generic APIs

o Innovative APIs

o Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)

o Monoclonal Antibodies

o Hormones

o Cytokines

o Recombinant Proteins

o Therapeutic Enzymes

o Vaccines

o Blood Factors

• Synthetic

o Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)

o Generic APIs

o Innovative APIs

Type of Manufacturer Outlook (Revenue, USD Billion, 2018 - 2030)

• Captive APIs

• Merchant APIs

Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Generic APIs

• Innovative APIs

Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Cardiovascular Diseases

• Oncology

• CNS and Neurology

• Orthopedic

• Endocrinology

• Pulmonology

• Gastroenterology

• Nephrology

• Ophthalmology

• Others

Key Companies & Market Share Insights

Some of the leading players operating in the active pharmaceutical ingredients market include AbbVie, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., and Eli Lilly and Company. Key players are using existing customer bases in the region to prioritize maintaining high-quality standards and gain high market size access. This marketing strategy is useful for brands that have already built trust in the market. These players are heavily investing in advanced technology and infrastructure, allowing them to efficiently process & analyze a large volume of samples. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.

Evonik, CARBOGEN AMCIS, and Pharmazell, are some of the emerging market participants in the ophthalmic drugs market. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel product launches to capitalize on untapped avenues. 

Key Active Pharmaceutical Ingredients Companies:

• Dr. Reddy’s Laboratories Ltd.

• Sun Pharmaceutical Industries Ltd.

• Teva Pharmaceutical Industries Ltd.

• Cipla Inc.

• AbbVie Inc.

• Aurobindo Pharma

• Sandoz International GmbH (Novartis AG)

• Viatris Inc.

• Fresenius Kabi AG

• STADA Arzneimittel AG

Recent Developments

• In August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry.

• In July 2023, Teva Pharmaceutical Industries Ltd. designed a new strategy for development with potential sale of its API unit on the table. The API manufacturing facility is worth USD 2 billion.

• In June 2023, Lonza acquired Synaffix to improve its ADC services portfolio.

• In April 2023, Eli Lilly announced an investment of USD 1.6 billion in the U.S.-based LEAP Innovation Park. This brings the total investment to USD 3.7 billion to manufacture complex APIs for products such as genetic medicine.

• In February 2023, Lonza completed the manufacturing of its facility in Switzerland. The company enhanced its capacity for its High Potent Active Pharmaceutical Ingredient (HPAPI) manufacturing facility.

• In January 2023, Sterling Pharma Solutions acquired an API manufacturing facility from Novartis in Ringaskiddy, Ireland.

Order a free sample PDF of the Active Pharmaceutical Ingredients Market Intelligence Study, published by Grand View Research. 

[soumyafwr]

https://www.scoop.it/topic/healthcare-by-soumya-fw/p/4151019085/2024/02/16/oligonucleotide-synthesis-market-size-analysis-and-forecast-2031

Oligonucleotide Synthesis Market Size, Analysis and Forecast 2031

[axelreichel]

A full-size, high-density RNA microchip is about the size of a fingernail and can contain up to 780,000 unique RNA sequences, each covering an area of about 14 x 14 μm².

Tadika Kekić

The next generation of RNA chips

Research team achieves breakthrough: chemical synthesis of high-density RNA microarrays now faster and more efficient

An international research team led by the University of Vienna has succeeded in developing a new version of RNA building blocks with higher chemical reactivity and light sensitivity. This can significantly reduce the production time of RNA chips used in biotechnological and medical research. The chemical production of these chips is now twice as fast and seven times more efficient. The results of the research work were recently published in the renowned journal Science Advances.

The emergence and market approval of RNA-based medical products, such as mRNA vaccines during the COVID-19 pandemic, has also brought the RNA molecule into the public eye. RNA (ribonucleic acid) is an information-carrying polymer - a chemical compound made up of similar subunits - but with a far greater structural and functional diversity than DNA. About 40 years ago, a method for the chemical synthesis of DNA and RNA was developed in which any sequence can be assembled from DNA or RNA building blocks using phosphoramidite chemistry. A nucleic acid chain is built up step by step using these special chemical building blocks (phosphoramidites). Each building block carries chemical "protective groups" that prevent unwanted reactions and ensure the formation of a natural link in the nucleic acid chain.

Mastering challenges

This chemical method is also used in the production of microchips ("microarrays"), where millions of unique sequences can be synthesized and analyzed simultaneously on a solid surface the size of a fingernail. While DNA microarrays are already widely used, adapting the technology to RNA microarrays has proven difficult due to the lower stability of RNA.

Back in 2018, the University of Vienna demonstrated how high-density RNA chips can be produced using photolithography: By precisely positioning a beam of light, areas on the surface can be prepared for the attachment of the next building block through a photochemical reaction. Although this first report was a world first and remains unchallenged to this day, the method suffered from its long production time, low yield and low stability. Now this approach has been massively improved.

Development of a new generation of RNA building blocks

A team from the Institute of Inorganic Chemistry at the University of Vienna, in collaboration with the Max Mousseron Institute for Biomolecules at the University of Montpellier (France), has now developed a new version of RNA building blocks with higher chemical reactivity and light sensitivity. This advance significantly shortens the production time of RNA chips and makes synthesis twice as fast and seven times more efficient. The innovative RNA chips are capable of screening millions of RNA candidates for valuable sequences for a wide range of applications.

"The production of RNA microarrays with functional RNA molecules was simply out of reach with our previous setup. With the improved method using the propionyloxymethyl (PrOM) group as a protecting group, it is now possible," says Jory Lietard, Assistant Professor at the Institute of Inorganic Chemistry.

As a direct application of these improved RNA chips, the publication includes a study of RNA aptamers, small oligonucleotides that bind specifically to a target molecule. Two "glowing" aptamers were selected that produce fluorescence when binding to a dye, and thousands of variants of these aptamers were synthesized on the chip. A single binding experiment is sufficient to obtain data on all variants simultaneously, paving the way for the identification of improved aptamers with better diagnostic properties.

"High-quality RNA chips could be particularly valuable in the rapidly growing field of non-invasive molecular diagnostics. New and improved RNA aptamers are desperately sought, e.g. those that can track hormone levels in real time or monitor other biological markers directly from sweat or saliva," says Tadija Kekić, PhD student in Jory Lietard's group.

This work was financially supported by a joint grant from the Agence Nationale pour la Recherche/Austrian Science Fund (FWF Individual Project International I4923).

Original publication:

Publication in "Science Advances" T. Kekić, N. Milisavljević, J. Troussier, A. Tahir, F. Debart and J. Lietard: Accelerated, high quality photolithographic synthesis of RNA microarrays in situ https://www.science.org/doi/10.1126/sciadv.ado6762 doi: 10.1126/sciadv.ado6762